What to Eat on Retatrutide: An Evidence-Based Nutrition Guide

Retatrutide suppresses appetite more aggressively than any other GLP-1 drug in clinical development. In Phase 2 trials, participants on the 12mg dose lost an average of 24.2% of their body weight over 48 weeks — a level of weight loss previously seen only with bariatric surgery. That degree of appetite suppression creates a specific nutritional problem: people on retatrutide may not eat enough to meet their body's basic requirements.

This is not a theoretical concern. Recent research on GLP-1 receptor agonist users has documented widespread nutrient deficiencies, dangerously low caloric intake, and protein consumption far below recommended levels. These findings come from the broader GLP-1 drug class — semaglutide and tirzepatide users — and there is reason to believe the problem could be more pronounced with retatrutide, given its stronger appetite-suppressing mechanism.

This page reviews what the published research shows about nutrition during GLP-1 therapy, what retatrutide's unique triple-agonist mechanism means for dietary needs, and what the evidence suggests about how to eat while on this drug.

Retatrutide is an investigational drug that has not been approved by the FDA. Nothing on this page constitutes medical advice. Consult your healthcare provider for personalized dietary guidance.

The Nutrition Problem with GLP-1 Drugs

Two recent studies have documented how poorly GLP-1 drug users eat — not by choice, but because the drugs suppress appetite so effectively that people struggle to consume adequate nutrition.

Study 1: Nutrient Intake on GLP-1 Receptor Agonists

A cross-sectional study published in Frontiers in Nutrition (April 2025) examined 69 adults who had been using a GLP-1 receptor agonist for at least one month. Participants completed 3-day food records, and their nutrient intake was compared to the Dietary Reference Intakes (DRI).

The findings were striking. Participants had insufficient intake of multiple essential nutrients:

Participants also overconsumed fat (39.9% of total calories) and saturated fat. Their protein intake was technically within the Acceptable Macronutrient Distribution Range by percentage, but on a grams-per-kilogram basis — the measure that actually matters for preserving muscle during weight loss — protein intake was significantly below daily needs.

The authors concluded that "patient-centered nutritional guidance is essential to optimize health outcomes and prevent unintended health consequences."

Study 2: Caloric Intake on GLP-1 and Dual Agonists

A larger study published on Research Square (September 2025) surveyed 387 adults using GLP-1 or dual GIP/GLP-1 agonists. Participants completed 48-hour food diaries.

The average daily caloric intake was 753 calories — roughly one-third of what most adults need. Average protein intake was just 33.4 grams per day, and fewer than 10% of participants met recommended protein levels.

The study also found that higher total protein intake was a significant predictor of weight loss success (beta = 0.446, p = 0.014). In other words, people who ate more protein lost more weight — not less. This finding aligns with broader weight loss research showing that adequate protein intake supports fat loss while preserving metabolically active lean tissue.

Why Retatrutide May Amplify This Problem

The studies above examined users of semaglutide and tirzepatide — drugs that target one or two receptors. Retatrutide targets three: GLP-1, GIP, and glucagon. Each of these contributes to appetite suppression through different pathways, and the combined effect is stronger than either drug alone.

This means retatrutide users face potentially the most severe appetite suppression of any weight loss drug currently in development. If semaglutide users are already averaging 753 calories per day, the risk of under-eating on retatrutide — particularly during the higher dose phases — is a real concern.

There is no published data on the dietary intake of retatrutide clinical trial participants. The inferences on this page are drawn from the GLP-1 class research above and from retatrutide's known pharmacology.

The Glucagon Factor: What Makes Retatrutide Different

Retatrutide is the only advanced clinical candidate that activates the glucagon receptor alongside GLP-1 and GIP. This has specific nutritional implications that do not apply to semaglutide (GLP-1 only) or tirzepatide (GLP-1 + GIP).

Glucagon and Glycogen

Glucagon's primary physiological role is to mobilize stored energy. It stimulates hepatic glycogenolysis — the breakdown of glycogen (the body's stored form of carbohydrate) in the liver to release glucose into the bloodstream. It also promotes gluconeogenesis, the creation of new glucose from non-carbohydrate sources.

In normal physiology, glucagon rises during fasting to maintain blood sugar. With retatrutide, the glucagon receptor is being activated pharmacologically on top of natural glucagon signaling. The theoretical concern is that chronic glucagon receptor agonism could accelerate glycogen depletion, particularly if carbohydrate intake is very low.

No study has directly measured glycogen stores in retatrutide users, and the concurrent GLP-1 and GIP agonism may partially offset glucagon's glucose-raising effects. However, the pharmacology suggests that retatrutide users may have a higher functional need for dietary carbohydrate than users of GLP-1-only drugs — not a lower one.

This is relevant because many people on weight loss drugs gravitate toward low-carbohydrate or ketogenic diets. While this approach may work with semaglutide or tirzepatide, it could be counterproductive with retatrutide if it leads to glycogen depletion on top of pharmacological glucagon activation.

Glucagon and Energy Expenditure

Glucagon receptor activation increases resting energy expenditure — the number of calories burned at rest — through mechanisms including thermogenesis in brown adipose tissue and increased hepatic fatty acid oxidation. This is one of the reasons retatrutide produces more weight loss than drugs without glucagon activity.

However, increased energy expenditure means the body needs more fuel. If a retatrutide user is eating 750-1,000 calories per day while simultaneously burning more calories at rest due to glucagon-mediated thermogenesis, the energy deficit could become extreme. An extreme deficit accelerates lean mass loss, reduces metabolic rate, and increases the risk of fatigue, hair loss, and nutrient deficiencies.

Protein: The Most Important Dietary Priority

Across the published research on GLP-1 drugs and weight loss, one finding is consistent: adequate protein intake is the single most important dietary factor for preserving muscle during drug-assisted weight loss.

Why protein matters more on retatrutide

Retatrutide produces dramatic weight loss — 24.2% of body weight at the 12mg dose over 48 weeks. With weight loss of this magnitude, lean mass loss is inevitable. DXA body composition data from retatrutide's Phase 2 sub-study, published in The Lancet Diabetes & Endocrinology (June 2025), confirmed that lean mass loss occurs alongside fat loss, consistent with patterns seen across the GLP-1 drug class.

Higher protein intake is the most well-established strategy for shifting the ratio of weight loss toward fat and away from muscle. The mechanism is straightforward: dietary protein provides amino acids that support muscle protein synthesis, and a higher protein intake during caloric deficit reduces the degree to which the body breaks down muscle for energy.

How much protein

A narrative review published in Obesity Pillars (August 2025) on nutrition interventions with GLP-1 therapies emphasized "adequate macronutrient, micronutrient and fluid intake, particularly increased protein intake alongside resistance training for the preservation of muscle mass."

General clinical guidance for protein intake during weight loss:

For someone on retatrutide, the 1.2-1.6 g/kg/day range is a reasonable starting point. At the higher doses where weight loss accelerates, aiming for the upper end of this range — combined with resistance exercise — is the most evidence-supported approach.

Practical protein sources

When appetite is severely suppressed, calorie-efficient protein sources become important — foods that deliver a high amount of protein per bite, without requiring large volumes.

A practical approach: eat protein first at every meal. When appetite is limited, the protein portion of the meal should take priority over carbohydrates or fat, because the consequences of inadequate protein (muscle loss, reduced metabolic rate) are more difficult to reverse than the consequences of temporarily lower carbohydrate or fat intake.

Carbohydrates: A More Nuanced Question on Retatrutide

Carbohydrate intake during weight loss is a debated topic in general nutrition. On retatrutide, the question has an additional layer of complexity because of the glucagon receptor component.

Why very low carbohydrate diets may not be ideal

As discussed above, retatrutide's glucagon agonism accelerates the breakdown of glycogen. On a very low carbohydrate diet (under 50g/day), glycogen stores are already limited. Adding pharmacological glucagon activation on top of dietary carbohydrate restriction could theoretically lead to rapid glycogen depletion, contributing to fatigue, dizziness, brain fog, and poor exercise performance.

This does not mean carbohydrate intake needs to be high. It means that the extreme carbohydrate restriction popular in some weight loss communities may be particularly unsuitable for retatrutide users.

No clinical study has tested different carbohydrate intakes in retatrutide users. This is mechanistic inference, not established clinical guidance.

Practical carbohydrate recommendations

A moderate carbohydrate intake — approximately 100-150g per day from whole food sources — provides enough substrate to maintain glycogen stores without adding excessive calories. Emphasis should be on complex carbohydrates that provide additional nutrients:

• Oats — fiber, B vitamins, magnesium
• Sweet potato — vitamin A, potassium, fiber
• Brown rice or quinoa — sustained energy, B vitamins
• Fruit — vitamin C, potassium, fiber, natural sugars for glycogen replenishment
• Legumes — also provide protein, fiber, iron, and magnesium

Managing GI Side Effects Through Diet

Gastrointestinal side effects — nausea, diarrhea, constipation, and vomiting — are the most common adverse events with retatrutide, reported in 33-43% of participants in the TRIUMPH-4 trial. Dietary choices can significantly influence the severity of these symptoms.

Foods that tend to worsen GI symptoms

Retatrutide slows gastric emptying as part of its appetite-reducing mechanism. Foods that further delay gastric emptying or are difficult to digest can compound this effect:

• High-fat and fried foods — fat is the slowest macronutrient to digest; adding high-fat meals to an already slowed stomach increases nausea risk
• Large meals — volume exacerbates delayed gastric emptying; the stomach simply cannot process large quantities efficiently
• Carbonated beverages — gas and bloating on top of slowed digestion
• Very spicy foods — can irritate an already sensitized GI tract
• Raw vegetables in large quantities — raw fiber is harder to digest than cooked; large salads may sit heavily

Foods that tend to help

• Ginger — ginger tea or crystallized ginger has established antiemetic properties and is commonly recommended for GLP-1-related nausea
• Bone broth — hydration, electrolytes, and protein in an easily digestible liquid form
• Cooked vegetables — softened fiber is gentler on slowed digestion than raw
• Smaller, more frequent meals — four to five smaller meals distributes digestive load throughout the day
• Room-temperature or cool foods — hot foods can worsen nausea for some people

Micronutrient Gaps to Watch

The Frontiers in Nutrition data showed that GLP-1 drug users are deficient in multiple vitamins and minerals. When food intake drops below 1,200-1,500 calories per day, it becomes nearly impossible to meet micronutrient needs through food alone.

Supplements worth discussing with a healthcare provider

A daily multivitamin can serve as baseline insurance, but the deficiencies documented in the research are large enough that targeted supplementation may be more appropriate for some individuals. This is a conversation for a healthcare provider or registered dietitian, not a self-directed decision.

A Sample Day: What Adequate Nutrition Looks Like

This is not a prescriptive meal plan — individual needs vary based on body weight, activity level, health status, and how the drug affects appetite at each dose. This is an illustration of what roughly adequate nutrition looks like in terms of targets.

Daily totals: approximately 111g protein, 1,350 calories

For many retatrutide users — particularly at higher doses — these portions will feel large. The priority should be protein: if only part of a meal can be consumed, eat the protein portion first. The carbohydrate and vegetable components, while important, are secondary to meeting protein targets.

If eating solid food is difficult during dose escalation, liquid options (protein shakes, bone broth, smoothies made with Greek yogurt) can help bridge the gap. These are easier to consume when appetite is suppressed and are absorbed more readily when gastric emptying is slowed.

Adjusting by Dose Phase

Retatrutide's titration schedule — starting at 2mg and escalating to 8mg or 12mg — means appetite suppression intensifies over time. Dietary approach should adjust accordingly.

Weeks 1-4 (starting dose, 2mg)

Appetite reduction is typically mild at the starting dose. This is the time to establish habits: learn which high-protein meals work, identify foods that are tolerable, and begin building a routine. Caloric intake may drop modestly, but most people can still eat reasonably normal meals.

Weeks 5-12 (escalation phase, 4-8mg)

This is when appetite suppression typically becomes pronounced. Switching from three full meals to four or five smaller meals can help maintain adequate intake. Protein shakes become a useful tool for those who struggle to eat solid food. Nausea tends to peak during dose increases and improve between them.

Weeks 13+ (maintenance phase, 8-12mg)

By this stage, most people have adapted to the drug's effects and found a sustainable eating pattern. The body has typically adjusted to the GI side effects, and while appetite remains suppressed, the intensity of the initial adjustment period has passed. The focus shifts to maintaining protein intake and micronutrient sufficiency for the duration of treatment.

Injection day timing

Anecdotal reports from GLP-1 drug users suggest that appetite suppression and GI effects tend to be strongest in the 24-48 hours following injection. Some people find it helpful to eat a larger, protein-rich meal before their injection day and allow for lighter eating in the day or two afterward. This pattern has not been formally studied but is consistent with the pharmacokinetics of weekly-injection GLP-1 drugs.

Frequently Asked Questions

Sources

• Johnson, B., et al. (2025). Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study. Frontiers in Nutrition, 12. DOI: 10.3389/fnut.2025.1566498
• Stachowska, E., et al. (2025). Dietary intake patterns and nutritional adequacy among adults with overweight or obesity treated with GLP-1 or dual GIP/GLP-1 receptor agonists. Research Square (preprint). DOI: 10.21203/rs.3.rs-7640335/v1
• Mietlicki-Baase, E.G., et al. (2017). Daily supplementation of dietary protein improves the metabolic effects of GLP-1-based pharmacotherapy in lean and obese rats. Physiology & Behavior, 177, 122-128. DOI: 10.1016/j.physbeh.2017.04.017
• Fitch, A., et al. (2025). Application of nutrition interventions with GLP-1 based therapies: A narrative review of the challenges and solutions. Obesity Pillars, 16, 100205. DOI: 10.1016/j.obpill.2025.100205
• Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
• Eli Lilly and Company. (2025). Lilly's retatrutide achieved significant weight loss and pain relief in adults with obesity and knee osteoarthritis. Press release.

Medical Disclaimer

The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency.

Do not use this information to make decisions about your diet or health without consulting a qualified healthcare provider. The dietary recommendations on this page are based on general nutritional science and research from the broader GLP-1 drug class. No study has specifically examined dietary intake or nutritional outcomes in retatrutide users.

If you are enrolled in a retatrutide clinical trial, follow the dietary guidance provided by your trial physician. For personalized nutrition advice, consult a registered dietitian.

This site is not affiliated with Eli Lilly and Company or any pharmaceutical manufacturer.